Kenai Therapeutics Establishes Patient Advisory Board Portfolio News / By Karina Tin November 14, 2024 Kenai Therapeutics Establishes Patient Advisory Board Read More »
RAPT Therapeutics Reports Third Quarter 2024 Financial Results Portfolio News / By Karina Tin November 12, 2024 RAPT Therapeutics Reports Third Quarter 2024 Financial Results Read More »
ORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates Portfolio News / By Karina Tin November 12, 2024 ORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates Read More »
RAPT Therapeutics Stops Zelnecirnon Program Based on Recent FDA Feedback Following Clinical Hold Due to Single SAE of Severe Liver Injury Portfolio News / By Karina Tin November 11, 2024 RAPT Therapeutics Stops Zelnecirnon Program Based on Recent FDA Feedback Following Clinical Hold Due to Single SAE of Severe Liver Injury Read More »
A2 Bio Highlights Progress of Tmod TM CAR T-Cell Clinical Programs during 2024 Annual Meeting of the Society for Immunotherapy of Cancer Portfolio News / By Karina Tin November 9, 2024 A2 Bio Highlights Progress of Tmod TM CAR T-Cell Clinical Programs during 2024 Annual Meeting of the Society for Immunotherapy of Cancer Read More »
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Portfolio News / By Karina Tin November 6, 2024 Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Read More »
Remix Therapeutics™ Announces Publication in Science that Reveals Unprecedented Insights into Spliceosome Regulation and Alternative Splicing Portfolio News / By Karina Tin October 31, 2024 Remix Therapeutics™ Announces Publication in Science that Reveals Unprecedented Insights into Spliceosome Regulation and Alternative Splicing Read More »
Judo Bio Presents Data Demonstrating Mechanism of Receptor-mediated Delivery of Oligonucleotides Resulting in Gene Silencing in the Kidney Portfolio News / By Karina Tin October 26, 2024 Judo Bio Presents Data Demonstrating Mechanism of Receptor-mediated Delivery of Oligonucleotides Resulting in Gene Silencing in the Kidney Read More »
Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor Portfolio News / By Karina Tin October 24, 2024 Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor Read More »
Kenai Therapeutics Announces the Appointment of Dr. Derek Hei as Chief Technology Officer Portfolio News / By Karina Tin October 23, 2024 Kenai Therapeutics Announces the Appointment of Dr. Derek Hei as Chief Technology Officer Read More »
